In the small study, seven out of ten participants maintained low levels of HIV for several months after receiving the ...

Nearly 40,000 people in Khyber-Pakhtunkhwa are currently living with HIV/AIDS, while 15 to 20 new cases are being reported daily, provincial health officials revealed on World AIDS Day.Speaking at a ...

You may not realize you’ve benefited from HIV research. But if you’ve received a treatment that was approved through a recent ...

The Trump administration said that had the new prices been in effect last year, Medicare would have saved $12 billion, which ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read more on GILD stock here.

South Africa has taken a major step forward in expanding its HIV-prevention toolbox, with the Department of Health confirming that the National Essential Medicines List Committee (NEMLC) has approved ...

Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global health officials call a game-changer. The drug developed by Gilead ...

Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term. Researchers at Amsterdam UMC investigated whether this dysregulation can be prevented by ...

Oct 30 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for its new prevention drug Yeztugo, ...